Abstract. Statins, cholesterol-lowering drugs, are one of the most commonly prescribed types of medications. Previous studies have suggested that simvastatin may inhibit the cell function and tumor growth of hepatocellular carcinoma (HCC) cells; however, the molecular mechanisms underlying simvastatin-induced apoptosis in HCC cells remains to be elucidated. The aim of the present study was to investigate the role of simvastatin in the regulation of cell viability, proliferation and apoptosis in HepG2 and Huh7 HCC cells, and to elucidate the specific regulatory mechanisms by which simvastatin proceeds. MTT, trypan blue and flow cytometric analyses were performed in order to detect viability, proliferation and apoptosis in HepG2 and Huh7 cells. The results of the present study demonstrated that simvastatin significantly decreased cell viability and proliferation as well as increased apoptosis in HepG2 and Huh7 cells compared to that in untreated cells. In addition, reverse transcription quantitative polymerase chain reaction and western blot analysis revealed that simvastatin-treated cells exhibited increased expression levles of Notch1, p53, and Bax, as well as decreased expression levels of B cell lymphoma 2; furthermore, Notch1 upregulation resulted in the inhibition of Akt phosphorylation. In conclusion, the results of the present study indicated that simvastatin significantly promoted apoptosis in HCC cells, the mechanism of which may have proceeded via the upregualtion of the Notch1 gene in the Akt-dependent signaling pathway.
Introduction
Hepatocellular carcinoma (HCC) accounts for 80-90% of primary liver cancers and is one of the most prevalent malignant tumors in the world (1) . The incidence of HCC has steadily increased in Western countries over the past decade and the global incidence of HCC is predicted to continue to rise over the next few years (2, 3) . HCC has the third-highest rate of cancer-associated mortalities (4) and therefore studies into the effective treatment of HCC are essential.
Statins, cholesterol-lowering drugs, are one of the most commonly prescribed types of medications. Previous studies have focused on the use of statins as therapeutic agents for the treatment of solid and hematological cancers (5, 6, 7) . Statins have been shown to elicit pleiotropic effects on various cell types and differentially modulate cellular functions, including cell migration, proliferation, survival and apoptosis, in normal as well as malignant cells (8) . Simvastatin, a member of the statin family, was previously reported to regulate the migration, proliferation, apoptosis and growth of tumor cells (9, 10) ; in addition, Wang et al (11) demonstrated that simvastatin induced caspase-dependent apoptosis and activated p53 in OCM-1 cells. Kochuparambil et al (10) found that the inhibitory effect of simvastatin on prostate cancer cell growth occurred via the inhibition of the Akt pathway. Previous studies have suggested that simvastatin regulated arteriogenesis following stroke and enhanced the differentiation of bone marrow stromal cells into endothelial cells via the Notch signaling pathway (12, 13) ; this therefore indicated that the pharmacological manipulation of Notch signaling may be a promising novel strategy for the treatment of human disease.
Notch genes encode proteins which are activated via interaction with certain families of ligands (14, 15) 
Reverse transcription quantitative polymerase chain reaction (RT-qPCR).
Total RNA was isolated from transfected and non-transfected HepG2 cells using TRIzol ® reagent (Life Technologies, Inc., Rockville, MD, USA) according to the manufacturer's instructions. Reverse transcription was performed on 1 µg of total RNA from each sample using oligo (dT) primers and 200 units of SuperScript II (Life Technologies, Inc.) for extension. PCR amplification was performed using 1.25 U Ex Taq polymerase (Takara Bio, Inc., Dalian, China). All PCR products were resolved on 1.8% agarose gels containing ethidium bromide (Sigma-Aldrich). Primer pairs for human Notch1, p53, B cell lymphoma 2 (Bcl-2), Bcl-2-associated X protein (Bax), phosphorylated Akt (p-Akt), Akt and β-actin specific amplification of complementary DNA were as follows: Notch1 forward, 5'-CCG CAG TTG TGC TCC TGAA-3' and reverse, 5'-ACC TTG GCG GTC TCG TAG CT-3'; p53 forward, 5'-GAC CCA GGT CCA GAT GAA GCT-3' and reverse, 5'-ACC GTA GCT GCC CTG GTA GGT-3'; Bcl-2 forward, 5'-AGT TCG CCG AGA TGT CCA GGCA-3' and reverse, 5'-ACT TGT GGC CCA GAT AGG CACC-3'; Bax forward, 5'-ACA GGG TTT CAC CAG GATC-3' and reverse, 5'-GCT GCC ACC CGC AAG AAG AC-3'; p-Akt forward, 5'-GGA GAU CAU GCA GCA UCGC-3' and reverse, 5'-GCG AUG CUG CAU GAU CUCC-3'; Akt forward, 5'-CTT TCC AGA CCC ACG ACC-3' and reverse, 5'-CTC CGA GTG CAG GTA GTCC-3'; β-actin forward, 5'-GAG GCA CTC TTC CAG CCT TC-3' and reverse, 5'-GGA TGT CCA CGT CAC ACT TC-3' .
Western blot analysis. Cells were homogenized and lysed using radioimmunoprecipitation assay lysis buffer (100 mm NaCl; 50 mm Tris-HCl, pH 7.5; 1% TritonX-100; 1 mm EDTA; 10 mm β-glycerophosphate; 2 mm sodium vanadate; and protease inhibitor). Protein concentrations were assayed using the micro-bicinchoninic acid assay protein assay (Pierce Biotechnology, Inc., Rockford, IL, USA). Proteins (20-30 µg per lane) were separated using 10% SDS-PAGE and then electroblotted onto nitrocellulose membranes (GE Healthcare, Little Chalfont, UK). Non-specific binding was blocked by incubating with 5% non-fat milk in PBS with Tween 20 buffer (Sigma-Aldrich) at room temperature for 1 h. Cells were then incubated overnight at 4˚C with a 1:1,000 dilution of primary antibodies for Notch1 (monoclonal mouse anti-human), Akt (polyclonal rabbit anti-human), p-Akt (polyclonal rabbit anti-human), p53 (polyclonal rabbit anti-human), β-actin (monoclonal mouse anti-human), Bcl-2 (monoclonal mouse anti-human) and Bax (monoclonal mouse anti-human), all purchase from Sigma-Aldrich, followed by incubation with the corresponding horseradish peroxidase-conjugated goat anti-rabbit immunoglobulin (Ig)G and rabbit anti-mouse IgG (1:2,000; Sigma-Aldrich) at room temperature for 1 h. Antigens were then detected using the standard enhanced chemiluminescence kit (Santa Cruz Biotechnology, Inc., Dallas, TX, USA).
Statistical analysis.
All experiments were performed in triplicate, unless otherwise stated. Statistical analyses were performed using SPSS 13.0 software (SPSS, Inc., Chicago, IL, USA). Values are presented as the mean ± standard deviation. Statistical comparisons between groups were performed using a one-way analysis of variance followed by a Student's t test. P<0.05 was considered to indicate a statistically significant difference between values.
Results

Simvastatin inhibits HCC cell viability and proliferation.
The cytotoxic effects of various concentrations (0, 2, 4, 8, and 16 µM) and incubation periods (24, 48 , and 72 h) of simvastatin was examined in HepG2 and Huh7 cells using a trypan blue assay. As shown in Fig. 1 , simvastatin demonstrated high levels of cytotoxicity in HepG2 and Huh7 cells in a time-and dose-dependent manner. Following 72 h of simavastin treatment, even at the lowest dose (2 µM), the viability and proliferation of HepG2 and Huh7 cells was significantly decreased by >34 and 36%, respectively, compared to the untreated group. These results therefore indicated that simvastatin may be a promising anti-cancer drug for the treatment of HCC.
Simvastatin induces apoptosis in HepG2 and Huh7 cells.
Bcl-2 family genes have an important role in the regulation of apoptosis; Bcl-2 is an anti-apoptosis gene, while Bax is a pro-apoptosis gene (23) . In normal cells the expression of Bcl-2 and Bax is maintained at an equilibrium; however, during apoptosis, the expression of Bcl-2 is downregulated, while Bax is overexpressed (24) . In the present study FCM analysis was performed in order to determine whether apoptosis contributed to the simvastatin-induced reduction in HepG2 and Huh7 cell viability. As shown in Fig. 2A and B, HepG2 and Huh7 cells in the experimental groups demonstrated a marked increase in apoptosis in a time-and dose-dependent manner. In addition, Fig. 2C and D showed that the apoptosis-associated genes Bcl-2 and Bax had significantly altered expression in cells treated with simvastatin; mRNA expression levels of Bcl-2 were significantly decreased and expression levels of Bax were significantly increased in a time-and dose-dependent manner.
Simvastatin increases mRNA expression levels of Notch1 and p53. RT-qPCR was used in order to investigate the investigate its role in simvastatin-induced apoptosis. As shown in Fig. 4A and B, Notch1 was successfully knocked out in HepG2 cells. Following Notch1 siRNA transfection, the inhibitory effect of simvastatin on proliferation in HepG2 cells was markedly decreased (Fig. 4C) ; in addition, mRNA expression levels of p53 and Bax were downregulated compared to those of the control and mock siRNA-transfected groups (P<0.05) (Fig. 4D) .
Simvastatin inhibits the phosphorylation of Akt via upregulation of Notch1 expression in HepG2 cells. Western blot
analysis and RT-qPCR were performed in order to investigate the mechanism of simvastatin-induced HepG2 cell apoptosis by detecting the differential expression of the cell survival-associated gene Akt. As shown in Fig. 5 , simvastatin inhibited the phosphorylation of Akt in the control and mock siRNA-transfected groups; however, following Notch1 siRNA transfection, the inhibitory effect of simvastatin on p-Akt levels was significantly decreased (Fig. 5 ). This therefore indicated that simvastatin regulated the phosphorylation of Akt via increasing the expression of Notch1, which, in turn, resulted in HCC cell apoptosis. (32) (33) (34) . In addition, a study in Notch1-deficient mice demonstrated that Notch1 functioned as a tumor suppressor in mouse skin via inhibition of β-catenin signaling (35) . Another previous study provided novel evidence for the potential role of Notch1 signaling in modulating the state of human liver carcinoma (36, 37) . The results of the present study, showed that simvastatin inhibited HepG2 and Huh7 cell viability and proliferation, as well as promoted apoptosis; in addition, the anti-tumor effect of simvastatin was found to be associated with the Notch1 gene. This therefore indicated that simvastatin may inhibit HCC cell growth via regulation of Notch1 expression. These results were consistent with a previous study which showed that Notch1 arrested the cell cycle of HCC via cyclin A, cyclin D1, cyclin E and cdk4 (38) .
The aim of the present study was to investigate the role of Notch1 signaling in simvastatin-induced apoptosis in HepG2 and Huh7 cell by assessing the effect of Notch1 signaling on the expression of the apoptosis-associated proteins p53, Bax, and Bcl-2. The results showed that expression levels of p53 and Bax expression were significantly increased, whereas Bcl-2 expression was significantly decreased in a time-and dose-dependent manner. Previous studies have demonstrated that the overexpression of mutant or wild-type p53 may downregulate Bcl-2 expression, resulting in apoptotic cell death (39) . The results of the present study therefore indicated that following cell cycle arrest, Notch1 signaling induced apoptosis via a p53-dependent reduction in Bcl-2 pathway signaling.
Numerous studies have indicated that Akt kinase may be a noval target for cancer therapy (40) (41) (42) (43) . Experimental models have revealed an association between the regulation of survivin expression and increased Akt activity (44) . In prostate cancer cells, survivin expression was shown to be regulated by insulin-like growth factor 1 (IGF-1)-stimulated Akt-mTOR signaling (45) , which was impaired following simvastatin treatment (10) . Therefore, the present study investigated whether simvastatin-induced apoptosis in HepG2 and Huh7 cells was associated with the Akt pathway. The results demonstrated that simvastatin reduced levels of phosphorylated Akt in HCC cells. However, following Notch1 gene knock out, simvastatin had no effect on p-Akt expression. These results suggested that the mechanism of simvastatin-induced HCC cell apoptosis may proceed via regulation of the expression of the Notch1 gene, which has an important role in the Akt-dependent signaling pathway.
In conclusion, the results of the present study demonstrated that simvastatin treatment induced apoptosis in human HCC cell lines HepG2 and Huh7; in addition, simvastatin decreased cell viability and proliferation in a time-and dose-dependent manner. The anti-tumor effect of simvastatin was found to be associated with p53, Bcl-2 and Bax expression levels, as well as the Akt-dependent signaling pathway. The present study reinforced the anti-tumor effect of statins and provided evidence for the potential beneficial effects of simvastatin in HCC therapy in humans.
